Beta-adrenoblockers in patients with metabolic syndrome
Abstract
Aim. To study the effects of 16-week bisoprolol therapy on 24-hour blood pressure monitoring (BPM) data, carbohydrate and lipid metabolism, tissue insulin sensitivity, and cerebral perfusion (CB) in patients with mild to moderate arterial hypertension (AH) and metabolic syndrome (MS).
Material and methods. The study included 30 patients with I-II AH and MS receiving bisoprolol (5 mg/d). At baseline and after 3 months of the treatment, levels of total cholesterol (CH), high and low-density CH, triglycerides, fasting and postprandial glucose, and insulin were measured; 24-hour BPM and CP assessment were performed.
Results. Bisoprolol monotherapy was associated with substantial reduction in nighttime mean maximal and minimal systolic and diastolic BP, without significant changes in lipid profile, fasting and postprandial glycemia, or CP, comparing to baseline levels.
Conclusion. Due to its metabolically neutral effects, bisoprolol could be recommended in patients with carbohydrate and lipid metabolism disturbances.
About the Authors
V. B. Mychka
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
G. Kh. Sharipova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
N. V. Flegontova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
I. E. Chazova
A.L. Myasnikov Research Institute of Clinical Cardiology, Russian Cardiology Scientific and Clinical Complex, Federal Agency on High Medical Technologies. Moscow
Russian Federation
Russian Federation
References
1. Jonas M., Reicher-Reiss H., Royko V. et al. Usefullness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Am J Cardiol 1996; 77: 1273-7.
2. ISIS-1. First International Study of Infarct survival Collaborative Group. Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction. Lancet 1986; 2: 57-66.
3. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction (MIAMI). A randomized placebo-controlled international trial. Eur Heart J 1985; 6: 199-226.
4. Hjalmarson A., Esmefeldt D., Helritz J. et al. Effect on mortality of metoprolol in acute myocardial infarction. A double blind randomized trial. Lancet 1981; 2: 823-7.
5. CIBIS-II Investigators and Committees The Cardiac Insufficiency Bisoprolol Study II: a randomized trial. Lancet 1999;353: 9-13.
6. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. Br Med J 1998; 317: 713-9.
7. Janka H.U., Ziegler A.G., Disselhoff G., Mehnert H. Influece of bisiprolol on blood glucose, glucosuria and haemoglobin Al, in non-insulin-dependent diabetics. J Cardivasc Pharmacol 1986; 8 (Suppl. 11): S96-9.
8. Chang P.C., van Veen S., Vermeij P., van Brummelen P. Double-blind compason of the p 1-selectivity of single doses of bisoprolol and atenolol. J Cardiovasc Pharmacol 1986; 8 (Suppl 11): S58-60.
9. Asmar R.G., Kerihuel J.C., Girerd X.J., Safar M.E. Effect of bisoprolol on blood pressure and arterial hemodinamyc hypertension. Am J Cardiol 1991; 68: 61-4.
10. Vulpis V., Antonacci A., Prandi P. et al. The effects of bisoprolol and atenolol on glucose metabolism in hypertensive patients with non-insulin dependent diabetes mellitus. Minerva Med 1991; 82: 189-93.
11. Keck M. Einflup einer selektiven vs. Nicht-selektiven Betarezeptorblokade auf das Stoffwechselverhalten bei Ausdauer-bzw. Symptomlimitierter Belastung von Patienten mit stabilier Belastungskoronarinsuffizienz und Diabetes mellitus Тур Iia. Herz/Kreislauf 1995; 27: 256.
12. Bertel O., Marx B., Conen D. Effects of antihypertensive treatment on cerebral perfusion. Am J Med 1987; 82(3B): 29-36.
13. Meyer J.S., Rogers R.L., Mortel R.F. Prospective analysis of long-term control of mild hypertension in cerebral blood flow. Stroke 1985; 16:6:985-90.
14. Griffith D., James I.M., Newbury P.A., WooUard M.L. The effect of beta-adrenergic receptor bloacring drugs on cerebral blood flow. Br J Clin Pharmacol 1970; 7: 491-4.
15. Troisi E., Attanasio A., Matteis M. et al. Cerebral hemodinamics in young hypertensive subjects and effects of atenolol treatment. J Neurol Sci 1998; 15: 159: 1: 115-9.
Review
For citations:
Mychka V.B., Sharipova G.Kh., Flegontova N.V., Chazova I.E. Beta-adrenoblockers in patients with metabolic syndrome. Cardiovascular Therapy and Prevention. 2008;7(2):55-59. (In Russ.)
Views:
406
Email this article 
